DeepMed Research

Tianjin Medical University Cancer Institute & Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma

Phase 1

Not yet recruiting

Conditions: Peripheral T-cell Lymphoma

Interventions: Drug: Lposomal mitoxantrone hydrochloride,Cyclophosphamide,Vincristine,Etoposide and Prednisone(CMOEP)

First Posted Date: 2022-07-14

Last Posted Date: 2022-07-14

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 18

Registration Number: NCT05458180

Locations: 🇨🇳
Tianjin Medical University Cancer Insititute & Hospital, Tianjin, Tianjin, China

Conversion of Tislelizumab Combined With Chemotherapy in Unresectable Esophageal Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Unresectable
Esophageal Squamous Cell Carcinoma by AJCC V8 Stage

Interventions: Drug: tislelizumab+ Paclitaxel + Cisplatin

First Posted Date: 2022-07-08

Last Posted Date: 2022-07-08

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 40

Registration Number: NCT05449483

Locations: 🇨🇳
Hongjing Jiang, Tianjin, Tianjin, China

PD1 and PARP for Maintenance Therapy in NSLLC

Phase 2

Recruiting

Conditions: Lung Cancer

Interventions: Drug: PD-1 inhibitor
Drug: PARP inhibitor

First Posted Date: 2022-05-26

Last Posted Date: 2022-05-26

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 52

Registration Number: NCT05392686

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer

Phase 2

Not yet recruiting

Conditions: Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance

Interventions: Drug: RC48- ADC

First Posted Date: 2022-05-02

Last Posted Date: 2022-05-02

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT05356351

Granisetron Transdermal Patch System for Prevention of CINV by CapeOX

Phase 2

Conditions: Chemotherapy-induced Nausea and Vomiting

Interventions: Drug: Granisetron Transdermal Patch System

First Posted Date: 2022-04-13

Last Posted Date: 2022-04-13

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 57

Registration Number: NCT05325190

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer

Not Applicable

Conditions: Advanced HR+ HER2 Negative Breast Carcinoma

Interventions: Drug: (CDK)4/6 inhibitor

First Posted Date: 2022-03-24

Last Posted Date: 2022-09-29

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 500

Registration Number: NCT05295043

Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium

Completed

Conditions: Immunotherapy
Analgesia
Delirium
NSCLC

Interventions: Drug: neoadjuvant immunotherapy
Drug: Neoadjuvant chemotherapy

First Posted Date: 2022-03-10

Last Posted Date: 2024-01-05

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 81

Registration Number: NCT05273827

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
🇨🇳
Tianjin Chest Hospital, Tianjin, China
🇨🇳
Tianjin Medical University General Hospital, Tianjin, China

Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer

Phase 1

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Tislelizumab
Drug: Pemetrexed
Drug: Bevacizumab

First Posted Date: 2022-03-10

Last Posted Date: 2022-07-13

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT05273814

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Bevacizumab Combined With Double Dose Icotinib in Patients With EGFR Exon 21-L858R Mutation

Phase 2

Recruiting

Conditions: EGF-R Positive Non-Small Cell Lung Cancer
Tyrosine Kinase Inhibitor
Carcinoma, Non-Small-Cell Lung
Bevacizumab

Interventions: Drug: Bevacizumab and Icotinib

First Posted Date: 2022-03-03

Last Posted Date: 2023-01-17

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 35

Registration Number: NCT05263947

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma

Phase 2

Recruiting

Conditions: Intrahepatic Cholangiocarcinoma

Interventions: Drug: Sintilimab
Drug: IBI305
Drug: GEMOX

First Posted Date: 2022-02-23

Last Posted Date: 2022-02-23

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 90

Registration Number: NCT05251662

Locations: 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy